½ÃÀ庸°í¼­
»óǰÄÚµå
1371958

¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå ¿¹Ãø : Á¦Ç°º°, ÀûÀÀÁõº°, Áúȯº°, ´ë»ó ¿µ¿ªº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(-2030³â)

Digital Pills Market Forecasts to 2030 - Global Analysis By Product (Capsule, Tablet and Microchip Delivery Device), Indication, Disease, Target Area, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀåÀº 2023³â 6¾ï ´Þ·¯¸¦ Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.8%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç 2030³â¿¡´Â 17¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µðÁöÅÐ ¾Ë¾à´Â Åõ¾à°ú ÀüÀÚ ¸ð´ÏÅ͸µ ±¸¼º ¿ä¼Ò¸¦ °áÇÕÇÑ ÀÇ·á ±â¼úÀÇ ÇÑ À¯ÇüÀÔ´Ï´Ù. ½º¸¶Æ® ¾Ë¾à°ú ¼·Ãë °¡´ÉÇÑ ¼¾¼­·Îµµ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. º¹¾à Áؼö Çâ»ó, ¼·Ãë ÆÐÅÏ ÃßÀû, »ý¸®Àû µ¥ÀÌÅÍ ¸ð´ÏÅ͸µÀ» À§ÇØ ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ ¾Ë¾à¿¡´Â ÀϹÝÀûÀ¸·Î ½Ç¸®ÄÜ, ±¸¸®, ¸¶±×³×½· µîÀÇ ¿ø¼Ò·Î ±¸¼ºµÈ ¾ÈÀüÇÑ Àç·á·Î ¸¸µé¾îÁø ÀÛÀº ¼·Ãë °¡´É ¼¾¼­°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. µðÁöÅÐ ¾Ë¾àÀº ÀǾàǰ º¸Ãæ, ½Ç½Ã°£ ¸ð´ÏÅ͸µ, ¸ÂÃãÇü Ä¡·á °èȹ, ÀÓ»ó½ÃÇè ¹× Á¶»ç¸¦ Á¦°øÇÕ´Ï´Ù.

¹Ì±¹ Áßµ¶¼¾ÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 2018³â 18¼¼ÀÇ ¾à 300¸¸ ¸íÀÌ Á¤½ÅºÐ¿­ÁõÀ» ¾Î°í ÀÖ½À´Ï´Ù. Á¤½Å ºÐ¿­ÁõÀÇ À¯º´·ü Áõ°¡´Â µðÁöÅÐ ¾à¹° ºÎ¹®À» Å©°Ô Çâ»ó½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

³ëÀÎ ÀÇ·á¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡

³ëÀÎ Äɾî¿Í µðÁöÅÐ ¾Ë¾à¸¦ º´¿ëÇÏ¸é ³ëÀÎÀÇ °Ç°­°ú º¹Áö¸¦ Çâ»ó½ÃÄÑ ³ëÀÎÀÌ ¾È½ÉÇÏ°í ³ëÈĸ¦ º¸³¾ ¼ö ÀÖ½À´Ï´Ù. ³ëÀÎ ÀǾàǰ º¸Ãæ ¹× °Ç°­ È¿°ú¿¡ ´ëÇÑ ÆíÇâ ¾ø´Â µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á µðÁöÅÐ ¾Ë¾à´Â ³ë³â ÀÇÇÐ ¿¬±¸ ¹× ÀÓ»ó½ÃÇèÀÇ Áß¿äÇÑ ¿ä¼Ò°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¿©·¯ ¸¸¼º ÁúȯÀ» °¡Áø ³ëÀο¡°Ô´Â ´Ù¾çÇÑ ¾à¹°ÀÌ ÀÚÁÖ Åõ¿©µË´Ï´Ù. µðÁöÅÐ ¾Ë¾àÀ» »ç¿ëÇÏ¿© º¹ÀâÇÑ Ã³¹æ ¿ä¹ýÀ» °ü¸®ÇÏ°í ¾Ë¸²À» º¸³»°Å³ª º¹¿ë adherence¸¦ ¸ð´ÏÅ͸µÇÏ¿© Åõ¾à ½Ç¼öÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ °£º´Àο¡°Ô Å뺸, Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ, ³ëÀΠģȭÀûÀÎ ±â¼úÀÌ ½ÃÀå È®´ë¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

¾ö°ÝÇÑ ±ÔÁ¤

±ÔÁ¦ ´ç±¹ÀÇ ¸ð´ÏÅ͸µÀº µðÁöÅÐ ¾Ë¾à°¡ ÀǵµÇÑ ÀÇ·á ¸ñÀûÀ» ´Þ¼ºÇϴµ¥ È¿°úÀûÀÓÀ» º¸ÀåÇÕ´Ï´Ù. ±ÔÁ¦ ±â°üÀÇ °¡Àå Å« °ü½É»ç´Â µðÁöÅÐ ¾Ë¾àÀ» Æ÷ÇÔÇÑ ¸ðµç ÀÇ·á Á¦Ç°ÀÌ È¯ÀÚ¿¡°Ô ¾ÈÀüÇÏ°Ô »ç¿ëµÉ ¼ö ÀÖÀ½À» º¸ÀåÇÏ´Â °ÍÀÔ´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¤Àº ÀáÀçÀûÀ¸·Î À¯ÇØÇϰųª À§ÇèÇÑ ±â¼úÀÇ µµÀÔÀ» ¹æÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. µðÁöÅÐ ¾Ë¾à´Â ¾ÈÀü°ú È¿°ú¸¦ º¸ÀåÇϱâ À§ÇØ ±ÔÁ¦ ´ç±¹ÀÇ Ã¶ÀúÇÑ Á¶»ç¸¦ ¹Þ¾Æ¾ß ÇÕ´Ï´Ù. ÀÌ ¾ö°ÝÇÏ°í º¹ÀâÇÑ ÇÁ·Î¼¼½º´Â ½ÃÀå ¼ö¿ä¸¦ ¹æÇØÇÕ´Ï´Ù.

R&D Ȱµ¿ÀÇ È°¼ºÈ­

µðÁöÅÐ ¾Ë¾à ºÐ¾ß¿¡¼­´Â ¿¬±¸ °³¹ß(R&D) Ȱµ¿ÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¹è°æÀº ÀÌ ±â¼úÀÌ Åõ¾à °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ȯÀÚÀÇ °á°ú¸¦ °³¼±½Ãų ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ¾Ë¾àÀ» ¼·ÃëÇÑ ½ÃÁ¡À» Á¤È®ÇÏ°Ô °¨ÁöÇÒ ¼ö ÀÖ´Â º¸´Ù °í±Þ ¼¾¼­¸¦ °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ ¾Ë¾à ¸ÂÃã ¼³Á¤, »ç¿ëÀÚ Ä£È­ÀûÀÎ ÀÎÅÍÆäÀ̽º, ¹«¼± Åë½Å ÇÁ·ÎÅäÄÝ ¹× ¼ÒÇüÈ­¸¦ À§ÇÑ Á¶»ç Æ®·¹ÀÏÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

Á¦ÇÑµÈ È¯ÀÚ ¼ö¿ë¼º ¹× Àû¿ë¼º

µðÁöÅÐ ¾Ë¾à¿¡ ´ëÇÑ È¯ÀÚÀÇ ¼ö¿ë¼º°ú Àû¿ë¼ºÀÌ Á¦ÇÑÀûÀÎ °ÍÀº ÇÁ¶óÀ̹ö½Ã³ª º¸¾È¿¡ ´ëÇÑ ¿ì·Á, Âü½ÅÇÔ°ú Ä£¼÷ÇÔ, ±â¼úÀÇ ¿ÀÀÛµ¿À̳ª °íÀå¿¡ ´ëÇÑ ¿ì·Á, Á¦ÇÑµÈ ÀÔ¼ö¼º°ú Àú·ÅÇÑ µîÀÌ ¿øÀÎÀÔ´Ï´Ù. ¶ÇÇÑ È¯ÀÚ°¡ µðÁöÅÐ ¾Ë¾àÀ» ¹Þ¾ÆµéÀÌ´Â ½É¸®Àû À庮ÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ðµç ȯÀÚ¿Í º´¸®°¡ µðÁöÅÐ ¾Ë¾àÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ÀÌ ¸ðµç ¿äÀÎÀº ½ÃÀå ¼ö¿ä¸¦ ¹æÇØÇÕ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19ÀÇ Å« À¯ÇàÀº µðÁöÅÐ ¾Ë¾à ½ÃÀå¿¡ ±àÁ¤ÀûÀÌ°í ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. À¯ÇàÀº ¼¼°è °ø±Þ¸ÁÀÇ È¥¶õÀ» ÃÊ·¡ÇÏ¿© µðÁöÅÐ ¾Ë¾à°ú ±× ºÎǰÀÇ »ý»ê°ú À¯Åë¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ °Ç°­ ±â¼úÀ» Æ÷ÇÔÇÑ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¾×¼¼½º´Â ºÀ¼â ±â°£ µ¿¾È ƯÁ¤ Áý´ÜÀ¸·Î Á¦ÇѵǾú½À´Ï´Ù. ±×·¯³ª ¿ø°Ý ¸ð´ÏÅ͸µÀÇ Áß½Ã, ¸¸¼º Áúȯ °ü¸®ÀÇ Áß½Ã, ¿ø°Ý ÀÇ·á µµÀÔ Áõ°¡·Î ½ÃÀåÀº À¯ÀÍÇÑ ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù.

Á¤½Å ºÐ¿­Áõ ȯÀÚÀÇ ¼·Ãë ÃßÀû ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¤½Å ºÐ¿­Áõ ȯÀÚÀÇ ¼·Ãë ÃßÀû ºÎ¹®Àº À¯¸®ÇÑ ¼ºÀåÀ» ÀÌ·ç´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. Á¤½Å ºÐ¿­Áõ ȯÀÚ Áß ÀϺδ º´¸®Çаú °ü·ÃµÈ ½ºÆ¼±×¸¶¿¡ Á÷¸éÇÏ´Â »ç¶÷µéµµ ÀÖ½À´Ï´Ù. µðÁöÅÐ ¾Ë¾àÀº Á÷Á¢ °üÂûÇÒ ÇÊ¿ä ¾øÀÌ º¹¿ë adherence¸¦ ¸ð´ÏÅ͸µÇÏ´Â ´«¿¡ ¶çÁö ¾Ê´Â ¹æ¹ýÀ» Á¦°øÇÏ¿© ȯÀÚÀÇ ÀÚÀ²¼º°ú ÇÁ¶óÀ̹ö½Ã¸¦ º¸È£ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» Á¦°øÇϰí Àå±â°£¿¡ °ÉÃÄ º¹¾à Áؼö ÆÐÅÏÀ» ÃßÀûÇÕ´Ï´Ù. Á¶±â °³ÀÔ°ú Àç¹ß À§ÇèÀÇ °¨¼Ò´Â ÀÌ ºÐ¾ß ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»óµÇ´Â °ÍÀº º´¿ø ºÐ¾ßÀÔ´Ï´Ù.

º´¿ø ºÐ¾ß´Â ³·Àº ħ½À ¼ö¼ú Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí, º¹¾à Áؼö°¡ °¨¼ÒÇϰí, ¼¼°è ÀÔ¿ø°ú ¼ö¼úÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. Àü¹ÝÀûÀ¸·Î, ¿°Áõ¼º Àå Áúȯ(IBD) ȯÀÚÀÇ ±ÞÁõÀº º´¿øÀÌ Áø´Ü ÀýÂ÷ÀÇ Áß¿äÇÑ µµ±¸·Î µðÁöÅÐ ¾Ë¾à¸¦ äÅÃÇϵµ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® ÇÊÀº ºñħ½ÀÀûÀ̸ç Á¶±â ¹ß°ß ¹× Á¶±â Áø´ÜÀÌ °¡´ÉÇϱ⠶§¹®¿¡ ÀÌ ºÐ¾ß ¼ö¿ä¸¦ ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.

ÃÖ´ë Á¡À¯À² Áö¿ª

¾Æ½Ã¾ÆÅÂÆò¾çÀº °Ç°­ °ü¸® ÀÇ½Ä Áõ°¡, ±â¼ú Áøº¸, ¸¸¼º Áúȯ ºÎ´ã Áõ°¡·Î ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸¹Àº ±¹°¡µéÀº °Ç°­ °ü¸® ÀÎÇÁ¶ó, Á¢±Ù¼º ¹× ÁúÀ» Çâ»ó½Ã۱â À§ÇØ °Ç°­ °ü¸® ÁöÃâÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù. °¢±¹ÀÇ Á¤ºÎ´Â µðÁöÅÐ °Ç°­ ±â¼úÀÇ Ã¤¿ëÀ» ÃËÁøÇϱâ À§ÇÑ Á¤Ã¥°ú initiative¸¦ ½Ç½ÃÇß½À´Ï´Ù. ¶ÇÇÑ °í·ÉÈ­ Àα¸ Áõ°¡, ÀÓ»ó ¿¬±¸ ¹× Á¶»ç, °Ç°­ °ü¸® ÁöÃâ Áõ°¡ µîÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ °¡Àå ³ôÀº Áö¿ª:

ºÏ¹Ì´Â °­·ÂÇÑ ±â¼ú ÀÎÇÁ¶ó¿Í ³ëÈ­·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÏ¹Ì´Â °Ç°­ °ü¸® ¿¬±¸¿Í Çõ½ÅÀÇ ¼¼°è ¸®´õÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡´Â ¼ö¸¹Àº Á¦¾à ȸ»ç, ±â¼ú ±â¾÷ ¹× ¿¬±¸ ±â°üÀÌ ÀÖÀ¸¸ç µðÁöÅÐ °Ç°­ÀÇ Áøº¸¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì¿¡¼­´Â ½ÉÀ庴, ´ç´¢º´, °íÇ÷¾Ð µîÀÇ ¸¸¼º ÁúȯÀÌ À¯ÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ ±â¼ú°ú ÇÔ²² Á¤±âÀû ÀÎ °øµ¿ ¿¬±¸¿Í ÆÄÆ®³Ê½ÊÀÌ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃã¼³Á¤ ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ ÀÀÇÑ ÁÖ¿ä±¹ ½ÃÀå Ãß°è,¿¹Ãø ¹× º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(ÁÖ: Ÿ´ç¼º È®Àο¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼Ò°³
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç°ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾ »ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå : Á¦Ç°º°

  • ¼Ò°³
  • ĸ½¶
  • ¾Ë¾à
  • ¸¶ÀÌÅ©·ÎĨ Àü´Þ ÀåÄ¡

Á¦6Àå ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå : ÀûÀÀÁõº°

  • Á¤½Å ºÐ¿­Áõ ȯÀÚÀÇ ¼·Ãë »óȲ ÃßÀû
  • ¾ç±Ø¼º Àå¾Ö ȯÀÚÀÇ ¼·Ãë »óȲ ÃßÀû
  • ÁÖ¿ä ¿ì¿ïÁõ Àå¾Ö(MDD)

Á¦7Àå ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå : Áúȯº°

  • ¼Ò°³
  • ¾Ï
  • ´ç´¢º´
  • ¼øÈ¯±â Áúȯ
  • °¨¿°Áõ
  • Á¤½Å Àå¾Ö
  • ±âŸ º´

Á¦8Àå ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå : Ÿ°Ù Áö¿ªº°

  • ¼Ò°³
  • ½Äµµ
  • ¼ÒÀå
  • ´ëÀå
  • À§

Á¦9Àå ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå : ¿ëµµº°

  • ¼Ò°³
  • ĸ½¶ ³»½Ã°æ °Ë»ç
  • Ÿ°Ù ¾à¹° Àü´Þ
  • ¹ÙÀÌÅ» »çÀÎ ¸ð´ÏÅ͸µ

Á¦10Àå ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³
  • º´¿ø
  • Áø´Ü¼¾ÅÍ
  • ÀçÅà ġ·á ȯ°æ
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦11Àå ¼¼°è µðÁöÅÐ ¾Ë¾à ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦12Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷ ¹× ÇÕÀÛÅõÀÚ(JV)
  • Àμö ¹× ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Abbott Laboratories
  • Proteus Digital Health Inc.
  • Pure Tech
  • Medtronic
  • 2morrow Inc.
  • Gentag Inc.
  • AnX Robotica Corporation
  • CapsoVision Inc.
  • Teladoc Health Inc.
  • Microchips Biotech Inc.
  • Omada Health Inc
  • Otsuka Holdings Co Limited
  • Livongo Health
  • Novartis AG
  • Leaf Healthcare Inc
  • Perficient Inc
  • AliveCor Inc
  • WellDoc Inc
  • Mocacare
  • iRhythm Technologies Inc
JHS 23.11.10

According to Stratistics MRC, the Global Digital Pills Market is accounted for $0.6 billion in 2023 and is expected to reach $1.7 billion by 2030 growing at a CAGR of 11.8% during the forecast period. Digital pills are a type of medical technology that combines medication with electronic monitoring components. They are also known as smart pills or ingestible sensors. They are designed to improve medication adherence, track ingestion patterns, and monitor physiological data. It contains a tiny ingestible sensor made of safe materials, typically composed of elements like silicon, copper, and magnesium. Digital pills provide medication adherence, real-time monitoring, customized treatment plans, clinical trials and research.

According to the American Addiction Center, in the U.S., around of 3 million people aged 18 suffered from Schizophrenia in 2018. The rising prevalence of Schizophrenia is expected to provide a significant boost to the digital pills sector.

Market Dynamics:

Driver:

Rising awareness of geriatric care

The combination of geriatric care with the use of digital pills improves elderly people's health and well-being, enabling them to age in place with assurance and support. By offering unbiased data on medication adherence and health effects in senior people, digital pills can be a key component of geriatric research and clinical trials. A range of drugs are frequently administered to older people who have several chronic diseases. The risk of medication mistakes can be decreased by using digital pills to manage complicated prescription regimens by sending out reminders and monitoring adherence. Additionally, its notifications to care givers, ongoing surveillance, and age-friendly technology are boosting the market's expansion.

Restraint:

Strict regulations

Regulatory oversight ensures that digital pills are effective in achieving their intended medical purposes. The primary concern of regulatory bodies is to ensure that any medical product, including digital pills, is safe for patients to use. Rigorous regulations help prevent the introduction of potentially harmful or risky technologies. Digital pills need to undergo thorough regulatory scrutiny to provide assurance of their safety and effectiveness. This strict and complex process hampers the market demand.

Opportunity:

Mounting R&D activities

There has been a surge in research and development (R&D) activities in the field of digital pills. This is driven by the potential of this technology to revolutionize medication management and improve patient outcomes. Researchers are working on developing more sophisticated sensors that can accurately detect when a pill is ingested. The research trails for customizations, user friendly interfaces, Wireless Communication Protocols and Miniaturization of digital pills are further accelerating the market growth.

Threat:

Limited patient acceptance & applicability

Limited patient acceptance and applicability for digital pills can be attributed by concerns about privacy and security, novelty and unfamiliarity, fear of technology malfunctions or failures, limited accessibility and affordability and so on. Also, patients may experience psychological barriers for accepting digital pills. In addition, not all patients or medical conditions may benefit from or be suitable for digital pills. All these factors are impeding the market demand.

COVID-19 Impact

The covid pandemic had both positive and negative impacts on the digital pills market. The pandemic led to disruptions in global supply chains, which have affected the production and distribution of digital pills and their components. In addition, access to healthcare services including digital health technologies has been limited for certain populations during lockdowns. But, due to increased emphasis on remote monitoring, focus on chronic disease management and telemedicine adoption the market has witnessed beneficial growth.

The tracking ingestion in schizophrenia patients segment is expected to be the largest during the forecast period

The tracking ingestion in schizophrenia patients segment is estimated to have a lucrative growth. Some individuals with schizophrenia may face stigma related to their condition. Digital pills provide a discreet way to monitor adherence without the need for direct observation, which can help preserve patient autonomy and privacy. Also, it provides personalized treatment plans and tracks adherence patterns over time. Its early intervention and reducing relapse risk is fuelling the segment demand.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, due to the rising demand for minimally invasive surgical treatments, poor medication adherence, and an increase in hospitalisations and surgical operations worldwide. Overall, the surge in inflammatory bowel disease (IBD) cases has prompted hospitals to embrace digital pills as a valuable tool in diagnostic procedures. The non-invasive nature of smart pills, coupled with their ability to enhance early detection & diagnosis is boosting the segment demand.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing healthcare awareness, technological advancements, and a rising burden of chronic diseases. Many countries in the Asia Pacific region have been increasing their healthcare spending to improve healthcare infrastructure, accessibility, and quality. Governments in various countries have been implementing policies and initiatives to promote the adoption of digital health technologies. Further, the growing aging population, clinical research & trials and rising healthcare expenditure are driving the market growth in this region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to its strong technological infrastructure and aging population. North America is a global leader in healthcare research and innovation. The region is home to numerous pharmaceutical companies, technology firms, and research institutions that drive advancements in digital health. Chronic diseases like heart disease, diabetes, and hypertension are prevalent in North America. The region's regular collaborations and partnerships along with continuous monitoring technologies is fuelling the market demand.

Key players in the market:

Some of the key players profiled in the Digital Pills Market include: Abbott Laboratories, Proteus Digital Health Inc., Pure Tech, Medtronic, 2morrow Inc., Gentag Inc., AnX Robotica Corporation, CapsoVision Inc., Teladoc Health Inc., Microchips Biotech Inc., Omada Health Inc, Otsuka Holdings Co Limited, Livongo Health, Novartis AG, Leaf Healthcare Inc, Perficient Inc, AliveCor Inc, WellDoc Inc, Mocacare and iRhythm Technologies Inc.

Key Developments:

In April 2023, Medtronic has announced the launch of MRI Care Pathway, a new system that can streamline the process of completing MRI scans for patients with Medtronic MRI compatible cardiac devices.

In February 2023, AnX Robotica Corp. (US) launched the NaviCam Small Bowel System in the US. The NaviCam SB System utilizes aspherical lens technology to reduce distortion and enhance the field of vision, a critical component in the diagnosis of small bowel disease.

Products Covered:

  • Capsule
  • Tablet
  • Microchip Delivery Device

Indications Covered:

  • Tracking Ingestion in Schizophrenia Patients
  • Tracking Ingestion in Biopolar Patients
  • Major Depressive Disorder (MDD)

Diseases Covered:

  • Cancer
  • Diabetes
  • Cardiovascular Disease
  • Infectious Diseases
  • Mental Disorders
  • Other Diseases

Target Areas Covered:

  • Esophagus
  • Small Intestine
  • Large Intestine
  • Stomach

Applications Covered:

  • Capsule Endoscopy
  • Targeted Drug Delivery
  • Vital Sign Monitoring

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Pills Market, By Product

  • 5.1 Introduction
  • 5.2 Capsule
  • 5.3 Tablet
  • 5.4 Microchip Delivery Device

6 Global Digital Pills Market, By Indication

  • 6.1 Introduction
  • 6.2 Tracking Ingestion in Schizophrenia Patients
  • 6.3 Tracking Ingestion in Biopolar Patients
  • 6.4 Major Depressive Disorder (MDD)

7 Global Digital Pills Market, By Disease

  • 7.1 Introduction
  • 7.2 Cancer
  • 7.3 Diabetes
  • 7.4 Cardiovascular Disease
  • 7.5 Infectious Diseases
  • 7.6 Mental Disorders
  • 7.7 Other Diseases

8 Global Digital Pills Market, By Target Area

  • 8.1 Introduction
  • 8.2 Esophagus
  • 8.3 Small Intestine
  • 8.4 Large Intestine
  • 8.5 Stomach

9 Global Digital Pills Market, By Application

  • 9.1 Introduction
  • 9.2 Capsule Endoscopy
  • 9.3 Targeted Drug Delivery
  • 9.4 Vital Sign Monitoring

10 Global Digital Pills Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Diagnostic Centers
  • 10.4 Home Care Settings
  • 10.5 Other End Users

11 Global Digital Pills Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Proteus Digital Health Inc.
  • 13.3 Pure Tech
  • 13.4 Medtronic
  • 13.5 2morrow Inc.
  • 13.6 Gentag Inc.
  • 13.7 AnX Robotica Corporation
  • 13.8 CapsoVision Inc.
  • 13.9 Teladoc Health Inc.
  • 13.10 Microchips Biotech Inc.
  • 13.11 Omada Health Inc
  • 13.12 Otsuka Holdings Co Limited
  • 13.13 Livongo Health
  • 13.14 Novartis AG
  • 13.15 Leaf Healthcare Inc
  • 13.16 Perficient Inc
  • 13.17 AliveCor Inc
  • 13.18 WellDoc Inc
  • 13.19 Mocacare
  • 13.20 iRhythm Technologies Inc
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦